Many people with inflammatory bowel disease (IBD) think carefully about diet, not just for comfort but because what they eat seems to influence how settled or reactive the gut feels. Two substances that come up repeatedly in gut health research, eicosapentaenoic acid (EPA), an omega-3 fatty acid, and butyrate, a short-chain fatty acid (SCFA), work through different routes but may support the gut lining and immune balance in complementary ways. Understanding how they operate helps explain why researchers are interested in whether the two together might offer more than either alone.
What are EPA and butyrate?
EPA is an omega-3 fatty acid found mainly in oily fish such as salmon, mackerel and sardines, and in some algae-derived supplements. It is a building block the body uses to make signalling molecules that influence inflammation.
Butyrate is a short-chain fatty acid produced when gut bacteria ferment dietary fibre in the colon. It is not obtained directly from food in meaningful amounts; it is generated locally by the microbiome from fibre that reaches the large bowel undigested.
Why this pairing matters for gut inflammation
In IBD, the gut lining can become more permeable, immune cells can become overactive, and the balance of gut bacteria often shifts away from fibre-fermenting, butyrate-producing species. EPA and butyrate interact with this picture from different angles: EPA affects chemical messengers that drive and resolve inflammation throughout the body, while butyrate acts locally in the colon, feeding the cells lining the gut and supporting immune regulation on site. Because IBD involves both systemic inflammatory signalling and local barrier dysfunction, a combined approach addressing both fronts is biologically plausible, though direct clinical trial evidence for this specific pairing remains limited.
Key mechanisms
EPA and inflammatory signalling
EPA is converted into eicosanoids and resolvins, molecules that help bring an inflammatory response to a close rather than letting it continue unchecked. By competing with omega-6 fatty acids, which tend to produce more pro-inflammatory signals, EPA can shift these messengers towards a calmer state. This does not switch off the immune system, but it may reduce the intensity and duration of inflammatory flare-ups at a cellular level.
Butyrate as fuel for the gut lining
Colonocytes, the cells lining the colon, rely on butyrate as their preferred energy source. A steady supply helps these cells maintain barrier function, the seal that normally keeps gut bacteria and their by-products separate from the immune system in the gut wall. When butyrate production falls, as often happens when the microbiome is disrupted, the lining can become more vulnerable, potentially allowing greater immune activation.
Butyrate and immune regulation
Beyond fuelling cells, butyrate interacts with receptors on immune cells and can support the development of regulatory T cells, which help keep inflammatory responses in check rather than letting them escalate. This immune-calming effect is one reason SCFAs interest researchers in conditions like ulcerative colitis, where local colonic inflammation is a defining feature.
Shared pathways and potential synergy
Both EPA and butyrate have been shown, in separate research, to influence NF-kB, a signalling pathway that acts as a master switch for many inflammatory genes. When overactive, it drives production of pro-inflammatory proteins called cytokines. Because EPA and butyrate may dampen this pathway through different entry points, one acting more systemically and the other more locally, there is a plausible rationale for exploring them together, though robust combined-therapy trials in humans are still needed.
A note on symptoms and medical treatment
Neither EPA nor butyrate is a substitute for prescribed IBD treatment; dietary strategies should sit alongside, not instead of, medical management. Symptoms such as bloating, discomfort or altered bowel habit do not always reflect active inflammation. The two can overlap, but they are not the same, and ongoing monitoring with a gastroenterologist remains essential.
Practical takeaways
- Include oily fish such as salmon, mackerel or sardines regularly if appropriate for your current diet and symptom stage.
- Discuss fibre tolerance with a dietitian, since fibre is the raw material gut bacteria need to produce butyrate, though needs vary with disease activity.
- Avoid relying on supplements without first discussing dosage and quality with your IBD team.
- Keep a consistent, rather than erratic, dietary pattern, since stability tends to support a more settled gut environment over time.
- Track symptoms and flares with your clinical team rather than self-diagnosing inflammation from symptoms alone.
Conclusion
EPA and butyrate work through distinct but potentially complementary routes: one shapes the body’s broader inflammatory signalling, the other supports the gut lining and local immune balance. While the biological rationale for combining them is reasonably strong, clinical evidence testing this specific pairing in people with IBD remains limited, and much of the mechanistic detail comes from laboratory and early-phase research. For now, the most realistic approach is steady, personalised dietary habits built alongside, not in place of, standard medical care. Long-term consistency, rather than short-term dietary fixes, remains the more reliable path towards gut stability.
References
- Scaioli E, Liverani E, Belluzzi A. The imbalance between n-6/n-3 polyunsaturated fatty acids and inflammatory bowel disease: a comprehensive review and future therapeutic perspectives. Int J Mol Sci. 2017;18(12):2619. doi:10.3390/ijms18122619.
- Marion-Letellier R, Savoye G, Ghosh S. Fatty acids, eicosanoids and PPAR gamma. Eur J Pharmacol. 2016;785:44-49. doi:10.1016/j.ejphar.2015.11.004.
- Scaioli E, Sartini A, Bellanova M, et al. Eicosapentaenoic acid reduces fecal levels of calprotectin and prevents relapse in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2018;16(8):1268-1275.e2. doi:10.1016/j.cgh.2018.01.036.
- Hamer HM, Jonkers D, Venema K, et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27(2):104-119. doi:10.1111/j.1365-2036.2007.03562.x.
- Vernia P, Marcheggiano A, Caprilli R, et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther. 1995;9(3):309-313. doi:10.1111/j.1365-2036.1995.tb00386.x.
- Parada Venegas D, De la Fuente MK, Landskron G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277. doi:10.3389/fimmu.2019.00277.
- Calder PC. Omega-3 fatty acids and inflammatory processes. Nutrients. 2010;2(3):355-374. doi:10.3390/nu2030355.
- Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8(5):349-361. doi:10.1038/nri2294.
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.